JWJo Wick

Jo Wick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jo Wick has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Near–Real-Time Clinical Trial Accrual Dashboard in a National Cancer Institute–Designated Cancer Center: Mixed Methods Implementation Study

    by Sam Pepper, Isuru Ratnayake, Mohammod Mahmudur Rahman, Robiul Islam Talukder, Saiful Islam Saif, Olivia Rippee, Ananda Jayawardhana, Tara Lin, Natalie Streeter, Byron Gajewski, et al.

    Background: Clinical trial accrual monitoring is a critical component of trial operations, influencing feasibility, timeliness, and scientific validity. Despite its importance, many National Cancer Institute–designated cancer centers continue to rely on static spreadsheets or manually generated reports that provide delayed and incomplete insight for study teams. These limitations hinder timely identification of recruitment challenges, reduce transparency across stakeholders, and constrain proactive operational decision‑making. Scalable, institution‑wide systems that support near–real‑time accrual oversight remain uncommon in academic settings. Objective: This study aimed to design, implement, and operationalize a near–real‑time clinical trial accrual dashboard within a National Cancer Institute–designated cancer center, and to evaluate its use, adoption, and early operational impact on accrual monitoring workflows. Methods: We developed an enterprise accrual dashboard integrating daily extracts from the institutional clinical trial management system with automated data quality validation and time series accrual forecasting. The system supported multiple stakeholder roles through role‑based access and was deployed within existing governance and oversight workflows. Implementation and evaluation were guided by the reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) framework and the Guidelines and Checklist for the Reporting on Digital Health Implementations framework, with system logs used to assess reach and adoption, and qualitative operational feedback used to characterize use in practice. Implementation (Results): From May 2022 to May 2026, the dashboard was used institution wide for monitoring therapeutic and nontherapeutic trials, logging 1605 unique user sessions across investigators, coordinators, data managers, and leaders. Automated daily validation enabled earlier detection and correction of missing or invalid accrual data, improving the reliability of institutional reporting over time. The dashboard replaced manual monthly reports with continuous monitoring and was incorporated into routine operational and leadership reviews, enabling earlier identification of lagging studies and more timely discussions regarding resource allocation and recruitment strategies. Accrual forecasting models demonstrated stable in sample and out of sample performance and were used to support anticipatory planning rather than prescriptive decision making. Initial increases in data correction workload and user resistance decreased as workflows matured and data transparency became normalized. Conclusions: Implementation of a near–real‑time accrual dashboard within an academic cancer center is feasible and sustainable and can meaningfully improve accrual oversight by strengthening data quality, transparency, and integration into routine workflows. The primary value of such systems lies not only in visualization or analytics but in their ability to shift accrual monitoring from retrospective reporting to proactive, institution‑wide operational review. With appropriate governance and clinical trial management system infrastructure, similar dashboards are transferable to other research centers seeking to modernize trial oversight.

  • Open Access

    Near–Real-Time Clinical Trial Accrual Dashboard in a National Cancer Institute–Designated Cancer Center: Mixed Methods Implementation Study (Preprint)

    by Sam Pepper, Isuru Ratnayake, Mohammod Mahmudur Rahman, Robiul Islam Talukder, Saiful Islam Saif, Olivia Rippee, Ananda Jayawardhana, Tara Lin, Natalie Streeter, Byron Gajewski, et al.

    BACKGROUND Clinical trial accrual monitoring is a critical component of trial operations, influencing feasibility, timeliness, and scientific validity. Despite its importance, many National Cancer Institute–designated cancer centers continue to rely on static spreadsheets or manually generated reports that provide delayed and incomplete insight for study teams. These limitations hinder timely identification of recruitment challenges, reduce transparency across stakeholders, and constrain proactive operational decision‑making. Scalable, institution‑wide systems that support near–real‑time accrual oversight remain uncommon in academic settings. OBJECTIVE This study aimed to design, implement, and operationalize a near–real‑time clinical trial accrual dashboard within a National Cancer Institute–designated cancer center, and to evaluate its use, adoption, and early operational impact on accrual monitoring workflows. METHODS We developed an enterprise accrual dashboard integrating daily extracts from the institutional clinical trial management system with automated data quality validation and time series accrual forecasting. The system supported multiple stakeholder roles through role‑based access and was deployed within existing governance and oversight workflows. Implementation and evaluation were guided by the reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) framework and the Guidelines and Checklist for the Reporting on Digital Health Implementations framework, with system logs used to assess reach and adoption, and qualitative operational feedback used to characterize use in practice. RESULTS From May 2022 to May 2025, the dashboard was used institution wide for monitoring therapeutic and nontherapeutic trials, logging 1605 unique user sessions across investigators, coordinators, data managers, and leaders. Automated daily validation enabled earlier detection and correction of missing or invalid accrual data, improving the reliability of institutional reporting over time. The dashboard replaced manual monthly reports with continuous monitoring and was incorporated into routine operational and leadership reviews, enabling earlier identification of lagging studies and more timely discussions regarding resource allocation and recruitment strategies. Accrual forecasting models demonstrated stable in sample and out of sample performance and were used to support anticipatory planning rather than prescriptive decision making. Initial increases in data correction workload and user resistance decreased as workflows matured and data transparency became normalized. CONCLUSIONS Implementation of a near–real‑time accrual dashboard within an academic cancer center is feasible and sustainable and can meaningfully improve accrual oversight by strengthening data quality, transparency, and integration into routine workflows. The primary value of such systems lies not only in visualization or analytics but in their ability to shift accrual monitoring from retrospective reporting to proactive, institution‑wide operational review. With appropriate governance and clinical trial management system infrastructure, similar dashboards are transferable to other research centers seeking to modernize trial oversight.

  • Improved mortality analysis in early‐phase dose‐ranging clinical trials for emergency medical diseases using Bayesian time‐to‐event models with active comparators

    by Xiaosong Shi, Jo A. Wick, Renee' L. Martin, Jonathan Beall, Robert Silbergleit, Gaylan L. Rockswold, William G. Barsan, Frederick K. Korley, Sarah Rockswold, Byron J. Gajewski

    Emergency medical diseases (EMDs) are the leading cause of death worldwide. A time‐to‐death analysis is needed to accurately identify the risks and describe the pattern of an EMD because the mortality rate can peak early and then decline. Dose‐ranging Phase II clinical trials are essential for developing new therapies for EMDs. However, most dose‐finding trials do not analyze mortality as a time‐to‐event endpoint. We propose three Bayesian dose‐response time‐to‐event models for a secondary mortality analysis of a clinical trial: a two‐group (active treatment vs control) model, a three‐parameter sigmoid EMAX model, and a hierarchical EMAX model. The study also incorporates one specific active treatment as an active comparator in constructing three new models. We evaluated the performance of these six models and a very popular independent model using simulated data motivated by a randomized Phase II clinical trial focused on identifying the most effective hyperbaric oxygen dose to achieve favorable functional outcomes in patients with severe traumatic brain injury. The results show that the three‐group, EMAX, and EMAX model with an active comparator produce the smallest averaged mean squared errors and smallest mean absolute biases. We provide a new approach for time‐to‐event analysis in early‐phase dose‐ranging clinical trials for EMDs. The EMAX model with an active comparator can provide valuable insights into the mortality analysis of new EMDs or other conditions that have changing risks over time. The restricted mean survival time, a function of the model's hazards, is recommended for displaying treatment effects for EMD research.

  • Open Access

    Using Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer center

    by Xiaosong Shi, Dinesh Pal Mudaranthakam, Jo A. Wick, David Streeter, Jeffrey A. Thompson, Natalie R. Streeter, Tara L. Lin, Joseph Hines, Matthew S. Mayo, Byron J. Gajewski


  • Open Access

    Data from Evaluating Work Impairment as a Source of Financial Toxicity in Cancer Healthcare and Negative Impacts on Health Status

    by Dinesh Pal Mudaranthakam, Nicole Nollen, Jo Wick, Dorothy Hughes, Danny Welch, Elizabeth Calhoun

    How the socioeconomic factors intersect for a particular patient can determine their susceptibility to financial toxicity, what costs they will encounter during treatment, the type and quality of their care, and the potential work impairments they face. The primary goal of this study was to evaluate financial factors leading to worsening health outcomes by the cancer subtype. A logistic model predicting worsening health outcomes while assessing the most influential economic factors was constructed by the University of Michigan Health and Retirement Study. A forward stepwise regression procedure was implemented to identify the social risk factors that impact health status. Stepwise regression was done on data subsets based on the cancer types of lung, breast, prostate, and colon cancer to determine whether significant predictors of worsening health status were different or the same across cancer types. Independent covariate analysis was also conducted to cross-validate our model. On the basis of the model fit statistics, the two-factor model has the best fit, that is, the lowest AIC among potential models of 3270.56, percent concordance of 64.7, and a C-statistics of 0.65. The two-factor model used work impairment and out-of-pocket costs, significantly contributing to worsening health outcomes. Covariate analysis demonstrated that younger patients with cancer experienced more financial burdens leading to worsening health outcomes than elderly patients aged 65 years and above. Work impairment and high out-of-pocket costs were significantly associated with worsening health outcomes among cancer patients. Matching the participants who need the most financial help with appropriate resources is essential to mitigate the financial burden.Significance:Among patients with cancer, work impairment and out-of-pocket are the two primary factors contributing to adverse health outcomes. Women, African American or other races, the Hispanic population, and younger individuals have encountered higher work impairment and out-of-pocket costs due to cancer than their counterparts.

  • Open Access

    Data from Evaluating Work Impairment as a Source of Financial Toxicity in Cancer Healthcare and Negative Impacts on Health Status

    by Dinesh Pal Mudaranthakam, Nicole Nollen, Jo Wick, Dorothy Hughes, Danny Welch, Elizabeth Calhoun

    How the socioeconomic factors intersect for a particular patient can determine their susceptibility to financial toxicity, what costs they will encounter during treatment, the type and quality of their care, and the potential work impairments they face. The primary goal of this study was to evaluate financial factors leading to worsening health outcomes by the cancer subtype. A logistic model predicting worsening health outcomes while assessing the most influential economic factors was constructed by the University of Michigan Health and Retirement Study. A forward stepwise regression procedure was implemented to identify the social risk factors that impact health status. Stepwise regression was done on data subsets based on the cancer types of lung, breast, prostate, and colon cancer to determine whether significant predictors of worsening health status were different or the same across cancer types. Independent covariate analysis was also conducted to cross-validate our model. On the basis of the model fit statistics, the two-factor model has the best fit, that is, the lowest AIC among potential models of 3270.56, percent concordance of 64.7, and a C-statistics of 0.65. The two-factor model used work impairment and out-of-pocket costs, significantly contributing to worsening health outcomes. Covariate analysis demonstrated that younger patients with cancer experienced more financial burdens leading to worsening health outcomes than elderly patients aged 65 years and above. Work impairment and high out-of-pocket costs were significantly associated with worsening health outcomes among cancer patients. Matching the participants who need the most financial help with appropriate resources is essential to mitigate the financial burden.Significance:Among patients with cancer, work impairment and out-of-pocket are the two primary factors contributing to adverse health outcomes. Women, African American or other races, the Hispanic population, and younger individuals have encountered higher work impairment and out-of-pocket costs due to cancer than their counterparts.

  • Open Access

    TABLE 2 from Evaluating Work Impairment as a Source of Financial Toxicity in Cancer Healthcare and Negative Impacts on Health Status

    by Dinesh Pal Mudaranthakam, Nicole Nollen, Jo Wick, Dorothy Hughes, Danny Welch, Elizabeth Calhoun

    The best-fit model – evaluating the financial factors across four cancer type patients (breast, lung, prostate, and colon)

  • Open Access

    TABLE 3 from Evaluating Work Impairment as a Source of Financial Toxicity in Cancer Healthcare and Negative Impacts on Health Status

    by Dinesh Pal Mudaranthakam, Nicole Nollen, Jo Wick, Dorothy Hughes, Danny Welch, Elizabeth Calhoun

    Logistic regression of full model of main effects

  • Open Access

    TABLE 2 from Evaluating Work Impairment as a Source of Financial Toxicity in Cancer Healthcare and Negative Impacts on Health Status

    by Dinesh Pal Mudaranthakam, Nicole Nollen, Jo Wick, Dorothy Hughes, Danny Welch, Elizabeth Calhoun

    The best-fit model – evaluating the financial factors across four cancer type patients (breast, lung, prostate, and colon)

  • Open Access

    TABLE 1 from Evaluating Work Impairment as a Source of Financial Toxicity in Cancer Healthcare and Negative Impacts on Health Status

    by Dinesh Pal Mudaranthakam, Nicole Nollen, Jo Wick, Dorothy Hughes, Danny Welch, Elizabeth Calhoun

    TABLE 1 from Evaluating Work Impairment as a Source of Financial Toxicity in Cancer Healthcare and Negative Impacts on Health Status